Comment on

• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Wolff AC, et al. J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30. J Clin Oncol. 2018. PMID: 29846122
• Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.

  Murray C, D'Arcy C, Gullo G, Flanagan L, Quinn CM. Murray C, et al. Arch Pathol Lab Med. 2019 Apr;143(4):412-413. doi: 10.5858/arpa.2018-0905-LE. Epub 2019 Jan 3. Arch Pathol Lab Med. 2019. PMID: 30605368 No abstract available.
• Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.

  Martin V, Valera A, De Joffrey M, Banfi S, Mazzucchelli L. Martin V, et al. Arch Pathol Lab Med. 2019 Apr;143(4):411-412. doi: 10.5858/arpa.2018-0904-LE. Epub 2019 Jan 3. Arch Pathol Lab Med. 2019. PMID: 30605369 No abstract available.